ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2026
Reduced Circulating Angiopoietin-Like Protein Levels in Crimean-Congo Hemorrhagic Fever.
Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Crimean-Congo Hemorrhagic Fever (CCHF) is a life-threatening zoonotic viral disease characterized by endothelial dysfunction, coagulopathy, and systemic inflammation. Angiopoietin-like proteins (ANGPTLs) regulate vascular integrity, lipid metabolism, and inflammatory responses; however, their roles in the pathogenesis of CCHF remain unclear. In this prospective case-control study, serum levels of ANGPTL1, ANGPTL2, ANGPTL3, ANGPTL4, ANGPTL6, and ANGPTL8 were measured by enzyme-linked immunosorbent assay (ELISA) in 60 patients with laboratory-confirmed CCHF and 30 healthy controls. Standard laboratory parameters were recorded, and correlations between ANGPTLs and inflammatory, coagulation, and metabolic markers were analyzed. Receiver operating characteristic (ROC) analysis was performed to assess diagnostic performance and exploratory mortality-discrimination ability. All measured ANGPTL levels were significantly lower in CCHF patients than in healthy controls. However, no statistically significant differences in ANGPTL1, ANGPTL2, ANGPTL3, ANGPTL4, ANGPTL6, or ANGPTL8 levels were observed between survivors and non-survivors. Although ANGPTL2 and ANGPTL3 yielded statistically significant area under the curve (AUC) values for mortality, the small number of fatal cases limits the strength of this finding. Overall, reduced ANGPTL levels were associated with disease-related inflammatory, endothelial, coagulation-related, and metabolic alterations, but these findings do not support their role as prognostic markers for mortality or establish a causal role in CCHF pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.